查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1541355

2024-2032 年按类型、治疗类型、最终用户和地区分類的卵巢癌市场报告

Ovarian Cancer Market Report by Type, Treatment Type, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年全球卵巢癌市场规模达21亿美元。卵巢癌发生率的上升、癌症护理中个人化医疗的出现以及政府提高意识、促进早期检测和支持研究的倡议的实施是推动市场的一些关键因素。

卵巢癌是一种始于卵巢的癌症，卵巢是负责产生卵子和雌性荷尔蒙的女性生殖器官。当卵巢中的异常细胞不受控制地生长和繁殖并形成肿瘤时，通常会发生这种情况。卵巢癌有不同类型，可以根据其起源的特定细胞进行分类。最常见的类型是上皮性卵巢癌，它起源于卵巢表面。其他较不常见的类型包括生殖细胞肿瘤和间质肿瘤，它们分别由产生卵子和荷尔蒙的细胞发展而来。卵巢癌的常见症状包括腹胀、骨盆或腹部疼痛、进食困难或很快就感到饱、频尿和排便习惯改变。

全球卵巢癌发生率不断上升推动了市场的发展。卵巢癌发生率的上升促使医疗保健提供者和製药公司大力投资研发，以发现创新疗法和标靶治疗。此外，医疗技术和诊断技术的进步导致了卵巢癌的早期检测和诊断，使医疗保健专业人员能够在早期阶段开始治疗，改善患者的治疗结果并提高存活率。此外，一般民众和医疗保健专业人员对定期筛检和早期检测重要性的认识不断增强，对于降低卵巢癌相关死亡率发挥着至关重要的作用。此外，製药公司和研究机构之间的策略合作和伙伴关係为开发新型疗法和个人化治疗方案铺平了道路。此外，一些地区医疗基础设施投资的不断增加以及优惠报销政策的出台，鼓励卵巢癌患者及时寻求全面治疗。

卵巢癌市场趋势/驱动因素：

卵巢癌盛行率不断上升

卵巢癌盛行率的不断上升是塑造全球卵巢癌市场动态的主要动力。卵巢癌是影响全世界女性最常见的妇科恶性肿瘤之一。据世界卫生组织 (WHO) 称，每年诊断出数以千计的新病例，使其成为重大的健康问题。人口老化和生活方式的改变，包括久坐的习惯和不健康的饮食，导致卵巢癌发生率上升。随着人口老化，罹患卵巢癌的风险增加，进一步增加了对有效治疗方案的需求。卵巢癌病例的激增刺激了製药公司和研究机构的广泛研究和开发工作，这正在影响市场的成长。

医疗技术和个人化医疗的技术进步

医疗技术和个人化医疗的进步开创了卵巢癌治疗的新时代，成为市场的重要动力。诊断工具和影像方式已经显着发展，使得卵巢癌的早期检测和准确诊断成为可能。经阴道超音波、磁振造影 (MRI) 和血清生物标记检测（例如 CA-125）提高了早期发现卵巢癌的机会，并提高了成功治疗的前景。此外，个人化医疗的兴起改变了癌症治疗的方法，包括卵巢癌。标靶疗法和免疫疗法的发展彻底改变了癌症治疗，提供针对个别患者肿瘤的特定分子和遗传特征的客製化治疗。这些精准治疗在临床试验中显示出有希望的结果，为先前治疗选择有限的卵巢癌患者带来了新的希望。

落实优惠报销政策

医疗基础设施的扩张和优惠报销政策的存在在推动全球卵巢癌市场的成长中发挥了关键作用。各国政府和医疗机构越来越多地投资于加强医疗设施，包括癌症治疗中心和肿瘤科。这一发展显着改善了卵巢癌患者获得医疗保健服务、诊断和治疗的机会。此外，优惠的报销政策减轻了寻求癌症治疗的患者的经济负担。对诊断测试、手术、化疗和标靶治疗的报销支持使更广泛的人群更负担得起并更容易获得治疗。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球卵巢癌市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：按类型

  • 上皮性卵巢癌
    • 市场趋势
    • 市场预测
  • 生殖细胞卵巢癌
    • 市场趋势
    • 市场预测
  • 基质细胞卵巢癌
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：依治疗类型

  • 免疫疗法
    • 市场趋势
    • 市场预测
  • 化疗
    • 市场趋势
    • 市场预测
  • 标靶治疗
    • 市场趋势
    • 市场预测
  • 手术
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：依最终用户

  • 医院
    • 市场趋势
    • 市场预测
  • 居家护理
    • 市场趋势
    • 市场预测
  • 专科中心
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AbbVie Inc.
    • Amneal Pharmaceuticals Inc.
    • AstraZeneca plc
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • GSK plc
    • Hikma Pharmaceuticals PLC
    • Lupin Limited
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112024A6407

The global ovarian cancer market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.1 Billion by 2032, exhibiting a growth rate (CAGR) of 10.09% during 2024-2032. The rising incidence of ovarian cancer cases, the emergence of personalized medicine in cancer care, and the implementation of government Initiatives to raise awareness, promote early detection, and support research represent some of the key factors driving the market.

Ovarian cancer is a type of cancer that begins in the ovaries, the female reproductive organs responsible for producing eggs and female hormones. It typically develops when abnormal cells in the ovaries grow and multiply uncontrollably, forming a tumor. There are different types of ovarian cancer, and they can be classified based on the specific cells from which they originate. The most common type is epithelial ovarian cancer, which arises from the surface of the ovary. Other less common types include germ cell tumors and stromal tumors, which develop from the cells that produce eggs and hormones, respectively. Common symptoms of ovarian cancer include abdominal bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, frequent urination, and changes in bowel habits.

The market is driven by the increasing prevalence of ovarian cancer cases globally. The rising incidence of ovarian cancer has prompted healthcare providers and pharmaceutical companies to invest heavily in research and development to discover innovative therapies and targeted treatments. Moreover, advancements in medical technology and diagnostic techniques have led to early detection and diagnosis of ovarian cancer, enabling healthcare professionals to initiate treatment at earlier stages, improving patient outcomes, and enhancing survival rates. Besides, the growing awareness among the general population and healthcare professionals about the importance of regular screenings and early detection plays a crucial role in reducing mortality rates associated with ovarian cancer. Additionally, strategic collaborations and partnerships between pharmaceutical companies and research institutions have paved the way for the development of novel therapeutics and personalized treatment options. Furthermore, the rising investment in healthcare infrastructure and the availability of favorable reimbursement policies in several regions have encouraged patients to seek timely and comprehensive treatment for ovarian cancer.

Ovarian Cancer Market Trends/Drivers:

Growing prevalence of ovarian cancer

The escalating prevalence of ovarian cancer is a primary driver shaping the dynamics of the global ovarian cancer market. Ovarian cancer is one of the most common gynecologic malignancies affecting women worldwide. According to the World Health Organization (WHO), thousands of new cases are diagnosed each year, making it a significant health concern. The aging population and changing lifestyle patterns, including sedentary habits and unhealthy diets, have contributed to the rising incidence of ovarian cancer. As the population ages, the risk of developing ovarian cancer increases, further intensifying the demand for effective treatment options. This surge in ovarian cancer cases has spurred extensive research and development efforts by pharmaceutical companies and research institutions, which is influencing the market growth.

Technological advancements in medical technology and personalized medicine

Advancements in medical technology and personalized medicine have ushered in a new era in the management of ovarian cancer, constituting a significant driver in the market. Diagnostic tools and imaging modalities have evolved significantly, enabling early detection and accurate diagnosis of ovarian cancer. Transvaginal ultrasounds, magnetic resonance imaging (MRI), and serum biomarker tests, such as CA-125, have improved the chances of detecting ovarian cancer at its early stages, enhancing the prospects for successful treatment. Moreover, the rise of personalized medicine has transformed the approach to cancer treatment, including ovarian cancer. The development of targeted therapies and immunotherapies has revolutionized cancer care, offering tailored treatments that address the specific molecular and genetic characteristics of individual patients' tumors. These precision treatments have shown promising results in clinical trials, providing new hope for ovarian cancer patients who may have previously had limited treatment options.

Implementation of favorable reimbursement policies

The expansion of healthcare infrastructure and the presence of favorable reimbursement policies have played a pivotal role in driving the growth of the global ovarian cancer market. Governments and healthcare authorities in various countries are increasingly investing in bolstering healthcare facilities, including cancer treatment centers and oncology units. This development has significantly improved patient access to healthcare services, diagnosis, and treatment for ovarian cancer. Furthermore, favorable reimbursement policies have alleviated the financial burden on patients seeking cancer treatments. Reimbursement support for diagnostic tests, surgeries, chemotherapy, and targeted therapies has made treatment more affordable and accessible to a broader segment of the population.

Ovarian Cancer Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global ovarian cancer market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on type, treatment type and end user.

Breakup by Type:

Epithelial Ovarian Cancer

Germ Cell Ovarian Cancer

Stromal Cell Ovarian Cancer

Epithelial ovarian cancer represents the leading type

The report has provided a detailed breakup and analysis of the market based on the type. This includes epithelial ovarian cancer, germ cell ovarian cancer, and stromal cell ovarian cancer. According to the report, epithelial ovarian cancer represented the largest segment.

Epithelial ovarian cancer is more commonly diagnosed in older women, and as the global population ages, the incidence of ovarian cancer tends to increase. The risk of developing ovarian cancer rises significantly after menopause, making postmenopausal women more susceptible to this type of cancer. Moreover, obesity and unhealthy lifestyle choices, such as poor diet and lack of physical activity, have been associated with an increased risk of ovarian cancer. The global rise in obesity rates over the past few decades may have contributed to the growing prevalence of epithelial ovarian cancer. Besides, certain genetic mutations, such as BRCA1 and BRCA2 mutations, are known to increase the risk of developing ovarian cancer. Inherited genetic factors can play a significant role in the prevalence of epithelial ovarian cancer, especially in families with a history of the disease.

Breakup by Treatment Type:

Immunotherapy

Chemotherapy

Targeted Therapy

Surgery

Others

Immunotherapy is the most popular treatment type

A detailed breakup and analysis of the market based on the treatment type has also been provided in the report. This includes lateral flow assays, dipsticks, microfluidics, molecular diagnostics, and immunoassays. According to the report, lateral flow assays hold the largest market share.

Immunotherapy has emerged as a revolutionary approach in cancer treatment, showing promising results in various cancer types. Ovarian cancer, being one of the deadliest gynecological malignancies, has been a focus of research to identify novel and more effective therapies. Immunotherapy's success in other cancer types has generated significant interest in exploring its potential benefits in ovarian cancer treatment. Moreover, immunotherapy focuses on targeting the tumor microenvironment, which includes various immune cells and signaling molecules that support tumor growth and progression. By modulating the immune response, immunotherapy aims to create an inhospitable environment for cancer cells, hindering their growth and spread.

Breakup by End User:

Hospitals

Homecare

Speciality Centre

Others

The report has provided a detailed breakup and analysis of the market based on end user. This includes hospitals, homecare, speciality centre, and others.

Hospitals are the primary healthcare institutions that play a crucial role in the diagnosis, treatment, and management of ovarian cancer. They offer a comprehensive range of medical services, including surgery, chemotherapy, radiation therapy, and supportive care for ovarian cancer patients. Hospitals typically have specialized oncology departments or cancer centers equipped with advanced medical technology and a multidisciplinary team of healthcare professionals, including oncologists, surgeons, nurses, and support staff.

Homecare services may include nursing care, administration of medications, pain management, wound care, and assistance with activities of daily living. Homecare is particularly beneficial for patients who require ongoing support and monitoring but prefer to receive treatment in a familiar environment. Homecare services aim to enhance the quality of life for ovarian cancer patients, allowing them to remain in their homes while receiving necessary medical attention.

Specialty centers are dedicated healthcare facilities that focus on specific medical conditions or diseases, including ovarian cancer. These centers offer specialized expertise, state-of-the-art facilities, and advanced treatment options tailored to the needs of ovarian cancer patients. Specialty centers include oncology clinics, cancer institutes, and women's health centers that provide comprehensive care, support, and access to cutting-edge therapies and clinical trials for ovarian cancer.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America accounts for the majority of market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (United States, Canada); Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others); Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others); Latin America (Brazil, Mexico, Others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America boasts a well-established and technologically advanced healthcare infrastructure, with a high concentration of hospitals, specialty centers, and cancer institutes equipped with state-of-the-art medical facilities and cutting-edge technologies. This enables efficient diagnosis, treatment, and follow-up care for ovarian cancer patients. Moreover, the region is a hub for biomedical research and development, with numerous pharmaceutical and biotechnology companies conducting extensive research on cancer therapies, including ovarian cancer. Ongoing research and clinical trials contribute to the development of innovative treatment options and novel drugs, making North America a frontrunner in ovarian cancer treatment advancements.

Competitive Landscape:

The competitive landscape of the ovarian cancer market is characterized by a mix of pharmaceutical companies, biotechnology firms, and academic institutions actively engaged in research, development, and commercialization of treatments and therapies. These companies are developing and commercializing chemotherapy drugs, targeted therapies, and immunotherapies for ovarian cancer treatment. They are also focusing on novel drug development and personalized treatment options. Moreover, various companies are identifying new drug targets, exploring combination therapies, and conducting clinical trials to assess the safety and efficacy of their investigational drugs. They are also forming strategic partnerships with academic institutions, research organizations, and other biopharmaceutical firms to access complementary expertise, resources, and technologies.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AbbVie Inc.

Amneal Pharmaceuticals Inc.

AstraZeneca plc

Eli Lilly and Company

F. Hoffmann-La

Roche AG

GSK plc

Hikma Pharmaceuticals PLC

Lupin Limited

Pfizer Inc.

Teva Pharmaceutical Industries Ltd.

Recent Developments:

In September 2022, AstraZeneca and Merck jointly declared that Lynparza (olaparib) had received approval in China for the maintenance treatment of adult patients diagnosed with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. This approval applies specifically to patients who have shown a complete or partial response to 1st-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD)-positive status.

In September 2022, Pfizer and Strata Oncology announced an expansion of their partnership to include a clinical trial that will evaluate multiple cancer therapies in novel, biomarker-guided patient cohorts.

Tesaro, which is now part of GlaxoSmithKline (GSK), launched "Zejula" (niraparib), another PARP inhibitor, for the treatment of ovarian cancer. Zejula is indicated for maintenance treatment in women with recurrent ovarian cancer who have responded to platinum-based chemotherapy.

Key Questions Answered in This Report:

  • How has the global ovarian cancer market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global ovarian cancer market?
  • What is the impact of each driver, restraint, and opportunity on the global ovarian cancer market?
  • What are the key regional markets?
  • Which countries represent the most attractive ovarian cancer market?
  • What is the breakup of the market based on types?
  • Which is the most attractive types in the ovarian cancer market?
  • What is the breakup of the market based on treatment type?
  • Which is the most attractive treatment type in the ovarian cancer market?
  • What is the breakup of the market based on the end user?
  • Which is the most attractive end user in the ovarian cancer market?
  • What is the competitive structure of the global ovarian cancer market?
  • Who are the key players/companies in the global ovarian cancer market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Ovarian Cancer Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Epithelial Ovarian Cancer
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Germ Cell Ovarian Cancer
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Stromal Cell Ovarian Cancer
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Treatment Type

  • 7.1 Immunotherapy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Chemotherapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Targeted Therapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Surgery
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Homecare
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Speciality Centre
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Amneal Pharmaceuticals Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 AstraZeneca plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eli Lilly and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 F. Hoffmann-La Roche AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 GSK plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Hikma Pharmaceuticals PLC
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Lupin Limited
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Pfizer Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Ovarian Cancer Market: Major Drivers and Challenges
  • Figure 2: Global: Ovarian Cancer Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Ovarian Cancer Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Ovarian Cancer Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Ovarian Cancer Market: Breakup by Treatment Type (in %), 2023
  • Figure 6: Global: Ovarian Cancer Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Ovarian Cancer Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Ovarian Cancer (Epithelial Ovarian Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Ovarian Cancer (Epithelial Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Ovarian Cancer (Germ Cell Ovarian Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Ovarian Cancer (Germ Cell Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Ovarian Cancer (Stromal Cell Ovarian Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Ovarian Cancer (Stromal Cell Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Ovarian Cancer (Immunotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Ovarian Cancer (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Ovarian Cancer (Chemotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Ovarian Cancer (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Ovarian Cancer (Targeted Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Ovarian Cancer (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Ovarian Cancer (Surgery) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Ovarian Cancer (Surgery) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Ovarian Cancer (Other Treatment Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Ovarian Cancer (Other Treatment Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Ovarian Cancer (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Ovarian Cancer (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Ovarian Cancer (Homecare) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Ovarian Cancer (Homecare) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Ovarian Cancer (Speciality Centre) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Ovarian Cancer (Speciality Centre) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Ovarian Cancer (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Ovarian Cancer (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: North America: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: North America: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: United States: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: United States: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Canada: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Canada: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Asia-Pacific: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Asia-Pacific: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: China: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: China: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Japan: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Japan: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: India: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: India: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: South Korea: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: South Korea: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Australia: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Australia: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Indonesia: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Indonesia: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Others: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Others: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Europe: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Europe: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Germany: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Germany: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: France: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: France: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: United Kingdom: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: United Kingdom: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Italy: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Italy: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Spain: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Spain: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Russia: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Russia: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Latin America: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Latin America: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Brazil: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Brazil: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Mexico: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Mexico: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Middle East and Africa: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Middle East and Africa: Ovarian Cancer Market: Breakup by Country (in %), 2023
  • Figure 80: Middle East and Africa: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Global: Ovarian Cancer Industry: SWOT Analysis
  • Figure 82: Global: Ovarian Cancer Industry: Value Chain Analysis
  • Figure 83: Global: Ovarian Cancer Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Ovarian Cancer Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Ovarian Cancer Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Ovarian Cancer Market Forecast: Breakup by Treatment Type (in Million US$), 2024-2032
  • Table 4: Global: Ovarian Cancer Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Ovarian Cancer Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Ovarian Cancer Market: Competitive Structure
  • Table 7: Global: Ovarian Cancer Market: Key Players